Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

Rhea-AI Summary

Guardant Health announced the presentation of studies at the IASLC 2022 World Conference on Lung Cancer in Vienna, focusing on its liquid biopsy tests' role in identifying treatment resistance mechanisms in lung cancer. Key findings will showcase the effectiveness of Guardant360, GuardantOMNI, and GuardantINFORM in advancing treatment strategies. Co-CEO Helmy Eltoukhy emphasized the significance of real-world data in improving patient outcomes. This event highlights Guardant Health's commitment to enhancing clinical decision-making in oncology.

Positive

• Studies at IASLC 2022 will showcase Guardant's liquid biopsy tests' impact on lung cancer treatment.
• Presentations will include data on treatment resistance mechanisms, aiding clinical decision-making.

Negative

• None.

Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360^™ to help physicians inform treatment decisions, GuardantOMNI^™ to advance cancer therapy trials, and GuardantINFORM™ for targeted drug development to improve outcomes for patients with lung cancer.

“We look forward to sharing new data at WCLC that demonstrate the utility of our liquid biopsy tests and datasets to create more accurate tumor profiles and impact outcomes for lung cancer patients around the world,” said Helmy Eltoukhy, Guardant Health co-CEO. “The data from retrospective and real-world analyses will show how blood-based tests provide critical insights into tumor evolution and treatment resistance throughout each lung cancer patient’s treatment journey and contribute more broadly to further developing the field of thoracic oncology.”

Full List of Presentations:

Guardant360

• Clinical and molecular profile of patients with non-small cell lung cancer (NSCLC) with incidental pathogenic germline variants detected in cfDNA (oral)
• Patterns of KEAP1 genomic co-alterations in advanced lung cancer as identified by plasma-based genotyping (e-poster)
• Germline HRR mutations in metastatic NSCLC and impact on progression-free survival: A single-center retrospective study (e-poster)
• Targetable alterations in non-small cell lung cancer according to age and sex (e-poster)
• Liquid biopsies first to make treatment decisions in patients with metastatic non-small cell lung cancer (NSCLC) (e-poster)
• Landscape of EGFR extracellular domain mutations in advanced non-small cell lung carcinoma (e-poster)
• The patient impact of liquid biopsy – health-related quality of life in patients undergoing liquid biopsy for advanced non-small cell lung cancer (e-poster)

GuardantINFORM

• Impact of germline BRCA1/2 alterations on EGFR mutant advanced non-small cell lung cancer outcomes (e-poster)
• Real-world landscape of EGFR C797X mutation as a resistance mechanism to osimertinib in non-small cell lung cancer (oral)

GuardantOMNI

• Durvalumab + olaparib vs. durvalumab alone as maintenance therapy in metastatic NSCLC: Outcomes from the phase 2 ORION study (poster)

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield^™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220805005190/en/

Investor Contact:

Alex Kleban

investors@guardanthealth.com

+1 657-254-5417

Media Contact:

Michele Rest

press@guardanthealth.com

+1 215-910-2138

Source: Guardant Health, Inc.

FAQ

What studies will Guardant Health present at IASLC 2022?

Guardant Health will present studies on the effectiveness of its liquid biopsy tests in identifying treatment resistance and informing lung cancer therapy.

When is the IASLC 2022 World Conference on Lung Cancer?

The IASLC 2022 World Conference on Lung Cancer is scheduled for August 6-9, 2022, in Vienna, Austria.

What is the significance of Guardant360 in lung cancer treatment?

Guardant360 provides critical insights into tumor profiles and helps physicians inform treatment decisions in patients with lung cancer.

How does Guardant Health contribute to cancer therapy trials?

Guardant Health advances cancer therapy trials by utilizing data from its tests to enhance understanding of treatment resistance mechanisms.